Table 1. Clinical characteristics .
| Characteristics | This cohort (n = 313) | MADIT II conventional (n = 490) | MADIT II defibrillator (n = 742) |
| Age | 67 ± 13* | 65 ± 10 | 64 ± 10 |
| Male sex (%) | 73* | 85 | 84 |
| NYHA functional class (%) | |||
| I | 31 | 39 | 35 |
| II | 27 | 34 | 35 |
| III | 42 | 23 | 25 |
| IV | 0 | 4 | 5 |
| Hypertension (%) | 57 | 53 | 53 |
| Diabetes (%) | 47* | 38 | 33 |
| Current or former cigarette smoker (%) | 38* | 82 | 80 |
| Coronary angioplasty (%) | 23* | 42 | 45 |
| Coronary bypass (%) | 6* | 56 | 58 |
| Atrial fibrillation (%) | 17* | 8 | 9 |
| BUN > 25 mg/dl (%) | 46* | 32 | 29 |
| QRS interval ≥ 0.12 sec | 33* | 51 | 50 |
| Non-specific conduction defect | 13* | 26 | 22 |
| Right bundle branch block | 9 | 7 | 9 |
| Left bundle branch block | 11* | 18 | 19 |
| LVEF (%) | 24 ± 5 | 23 ± 6 | 23 ± 5 |
| Medications (%) | |||
| Amiodarone | 7 | 10 | 13 |
| ACEi or ARB | 79 | 72 | 68 |
| Beta-blockers | 65 | 70 | 70 |
| Calcium-channel blockers | 5 | 9 | 9 |
| Class I antiarrhythmic agents | 1 | 2 | 3 |
| Digitalis | 13* | 57 | 57 |
| Diuretics | 63* | 81 | 72 |
| Statins | 25* | 64 | 67 |
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensinogen receptor blockers; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
* p < 0.025 in comparison among this cohort and both groups of the MADIT II study.